NCT01099774View on ClinicalTrials.gov

Safety and Efficacy of Different Formulations of Bimatoprost Ophthalmic Solution in Patients With Glaucoma or Ocular Hypertension

PHASE3CompletedINTERVENTIONAL
Enrollment

597

Participants

Timeline

Start Date

May 1, 2010

Primary Completion Date

April 29, 2011

Study Completion Date

April 29, 2011

Conditions
GlaucomaOcular Hypertension
Interventions
DRUG

Bimatoprost 0.03% Formulation B Ophthalmic Solution

One drop administered in each eye, every evening, for 12 weeks

DRUG

Bimatoprost 0.03% Ophthalmic Solution

One drop administered in each eye, every evening, for 12 weeks

Trial Locations (1)

Unknown

Newport Beach

Sponsors

Lead Sponsor

Allergan
All Listed Sponsors
lead

Allergan

INDUSTRY